Share This Page
Litigation Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2020)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2020)
| Docket | 1:20-cv-01333 | Date Filed | 2020-10-01 |
| Court | District Court, D. Delaware | Date Terminated | 2022-12-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,610,510; 10,610,511 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Apotex Inc.
Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-10-01 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2020)
Vanda v. Apotex (1:20-cv-01333): Litigation Summary, Claim Scope, and Patent-Entry Risk for Fanaptor (Fanaptor) and Related IP
Vanda Pharmaceuticals Inc. v. Apotex Inc., case number 1:20-cv-01333, is a US patent infringement litigation in federal district court. The docket and filings govern whether Apotex sought or can seek FDA approval for a generic or related product that would implicate Vanda’s patents tied to fanet aural? and its branded schizophrenia therapy portfolio. As the case-specific pleadings and the asserted patent list are not provided here, a complete, accurate, claim-level and timing-accurate litigation analysis cannot be produced.
What patents are asserted in Vanda Pharmaceuticals Inc. v. Apotex Inc. 1:20-cv-01333?
Answer: Not determinable from the provided information. A litigation analysis that identifies asserted U.S. patents, their expiration dates, and which claims cover which product manufacturing or formulation steps requires the complaint, answer, infringement contentions, and/or the judicial order listing asserted patents.
Which patent numbers and assignees are in the complaint?
Not determinable. The asserted patent numbers, assignees, and claim groupings (apparatus, composition, method-of-use, or manufacturing method) are not included in the prompt.
Are method-of-use, formulation, or process claims at issue?
Not determinable. The complaint must be reviewed to determine whether claims target:
- patient-treatment method-of-use,
- extended-release formulation properties,
- salt/crystalline form,
- manufacturing process parameters,
- or dosing regimens and titration schedules.
What is the litigation timeline for 1:20-cv-01333 (motions, hearings, schedules)?
Answer: Not determinable from the provided information. A meaningful litigation timeline requires docket entries (complaint filing, answer, Rule 16 scheduling, claim construction, summary judgment, trial dates, and any stay/settlement indicators).
Was the case stayed pending FDA resolution or related proceedings?
Not determinable. Many Hatch-Waxman cases enter stays tied to FDA approval pathways or to resolution of preliminary injunction motions.
Did the court hold a Markman (claim construction) and what were the outcomes?
Not determinable. Claim construction outcomes drive infringement and validity outcomes.
How do Vanda’s patent claims map to the allegedly infringing Apotex product?
Answer: Not determinable. Claim mapping requires:
- the asserted product description in the complaint and infringement contentions, and
- any ANDA or related regulatory submission references (including whether Apotex is pursuing a carve-out, a design-around formulation, or a different dosing strength/IR-vs-ER structure).
Is Apotex accused of infringing composition, method-of-use, or manufacturing claims?
Not determinable.
Did Apotex argue non-infringement via different release profile or formulation attributes?
Not determinable.
What generic entry risks exist for Apotex or other ANDA filers after 1:20-cv-01333?
Answer: Not determinable. Entry risks depend on:
- which patents are asserted and ultimately held valid,
- whether any patents are enjoined,
- the outcome of validity challenges under 35 USC 102/103/112,
- and whether FDA approval can proceed against remaining unexpired patents or exclusivity.
What are the exclusivity and patent-expiration constraints affecting entry?
Not determinable. Patent expiration dates and any statutory exclusivities (including new chemical entity or pediatric exclusivity) must be tied to the asserted patents.
What is the Orange Book status of Vanda’s patents implicated by 1:20-cv-01333?
Answer: Not determinable. Orange Book listings and patent-to-product mapping for each strength and dosage form require the specific drug and Orange Book patent numbers referenced by the complaint.
Was there a Paragraph IV challenge, and what did Vanda claim in response?
Answer: Not determinable. Whether the case is a Paragraph IV ANDA litigation and which section (e.g., 21 USC 355(j)(2)(A)(vii)) must be inferred from the complaint allegations and the notice of certification. No such detail is provided.
What settlement terms were reached, and what constraints apply to Apotex?
Answer: Not determinable. Settlement agreements, consent judgments, licensing terms, or covenant-not-to-sue language require a docket-based record or settlement filing.
How strong is Vanda’s patent estate in this specific dispute?
Answer: Not determinable. Litigation strength assessment requires:
- asserted claim set and their construction,
- asserted grounds of invalidity,
- prior art references cited in invalidity contentions,
- and any court rulings on dispositive motions.
What validity defenses were raised (obviousness, anticipation, indefiniteness)?
Not determinable.
Did the court grant summary judgment on infringement or invalidity?
Not determinable.
How does this case compare with other Vanda vs. generic challenges in schizophrenia therapeutics?
Answer: Not determinable. Comparison requires knowledge of:
- which drug(s) and patents are at issue here,
- outcomes in other cases (injunctions, stays, settlements),
- and whether courts have resolved claim construction consistently across disputes.
Commercial and regulatory impact: does the litigation affect FDA approval timing or launch sequencing?
Answer: Not determinable. The commercial impact depends on:
- whether Apotex is the only generic contestant,
- whether any exclusivity or court injunction blocks approval,
- and whether FDA approval triggers 180-day exclusivity for first filers.
Key Takeaways
- A precise litigation summary for Vanda Pharmaceuticals Inc. v. Apotex Inc., 1:20-cv-01333 requires the docket-specific record (asserted patents, claims, motions, rulings, and any settlement).
- The prompt does not include the complaint’s asserted-patent list, the ANDA/regulatory linkage, the claim set, or dispositive outcomes. A complete and accurate patent-expiration and entry-risk analysis cannot be produced from the provided information.
FAQs
-
What court presided over Vanda Pharmaceuticals v. Apotex (1:20-cv-01333)?
Not determinable from the provided information. -
Which asserted patents were at issue in Vanda’s infringement claims in 1:20-cv-01333?
Not determinable from the provided information. -
Was 1:20-cv-01333 an ANDA Paragraph IV litigation, and what certification was challenged?
Not determinable from the provided information. -
Did the case reach claim construction (Markman), and what did the court decide?
Not determinable from the provided information. -
What was the effect of the case on FDA approval timing or generic launch for Apotex?
Not determinable from the provided information.
References
No sources were provided in the prompt, and no court docket text or filings were included to cite.
More… ↓
